[
  {
    "ts": null,
    "headline": "2 Stocks to Buy With $5,000 and Hold for a Decade",
    "summary": "These two stocks come from completely different industries, but each could boost a long-term investor's returns.",
    "url": "https://finnhub.io/api/news?id=9a16d69ee0e505438ff48b7e168f3b5091531a73d8fc093cef203cd40484c699",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754836680,
      "headline": "2 Stocks to Buy With $5,000 and Hold for a Decade",
      "id": 136292515,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "These two stocks come from completely different industries, but each could boost a long-term investor's returns.",
      "url": "https://finnhub.io/api/news?id=9a16d69ee0e505438ff48b7e168f3b5091531a73d8fc093cef203cd40484c699"
    }
  },
  {
    "ts": null,
    "headline": "BofA Kept $200 Target on Zoetis (ZTS) as Competitive Threat Seen Modest",
    "summary": "Zoetis Inc. (NYSE:ZTS) is one of the best defensive stocks to invest in according to analysts. On July 10, Bank of America analyst Michael Ryskin reaffirmed a Buy rating on Zoetis with an unchanged price target of $200. His view remains constructive despite the recent FDA approval of Merck’s Bravecto Quantum, a new product that some […]",
    "url": "https://finnhub.io/api/news?id=1bdece107f60a0614a30df0226651d0fcff64115762c14686360ad72455fb656",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754798392,
      "headline": "BofA Kept $200 Target on Zoetis (ZTS) as Competitive Threat Seen Modest",
      "id": 136292388,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Zoetis Inc. (NYSE:ZTS) is one of the best defensive stocks to invest in according to analysts. On July 10, Bank of America analyst Michael Ryskin reaffirmed a Buy rating on Zoetis with an unchanged price target of $200. His view remains constructive despite the recent FDA approval of Merck’s Bravecto Quantum, a new product that some […]",
      "url": "https://finnhub.io/api/news?id=1bdece107f60a0614a30df0226651d0fcff64115762c14686360ad72455fb656"
    }
  }
]